The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer:the Maccabi Healthcare Services experience with a unified testing policy | אונקוטסט
מאמרים בשיתוף אונקוטסט
מאמרים בשיתוף אונקוטסט
אונקוטסט > מאמרים בשיתוף אונקוטסט > The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer:the Maccabi Healthcare Services experience with a unified testing policy

עדכונים > מאמרים בשיתוף אונקוטסט

The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer:the Maccabi Healthcare Services experience with a unified testing policy

 

The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer:the Maccabi Healthcare Services experience with a unified testing policy

Siegelmann-Danieli et al, 2013 ecancer medical sciences

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869476/

Authors:

Nava Siegelmann-Danieli, Barbara Silverman, Aviad Zick, Anat Beit-Or, Itzhak Katzir, and Avi Porath

צור קשר